These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23900878)

  • 1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
    Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
    Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
    Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
    J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
    Lindegger N; Sidharta PN; Reseski K; Dingemanse J
    Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
    Raja SG
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
    Sidharta PN; Melchior M; Kankam MK; Dingemanse J
    Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
    Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
    Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
    Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
    Krause A; Zisowsky J; Dingemanse J
    Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
    Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
    J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 14. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
    Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
    Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
    Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
    Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
    van Giersbergen PL; Dingemanse J
    Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
    Raghu G; Million-Rousseau R; Morganti A; Perchenet L; Behr J;
    Eur Respir J; 2013 Dec; 42(6):1622-32. PubMed ID: 23682110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.